Compare MobilEye Global Inc (MBLY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Novartis AG — how do they compare? MobilEye Global Inc trades at $7.1 (market cap $6.00B), while Novartis AG trades at $142.74 (market cap $268.57B). The key difference: Novartis AG is far larger — about 44.8× MobilEye Global Inc's market cap, and Novartis AG pays a 3.31% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Novartis AG for 82 Days on average.
| MBLY | NVS | |
|---|---|---|
Market Cap | $6.00B | $268.57B |
Volume | 7,007,849 | 1,532,573 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.42 | $168.62 |
52-Week Low | $6.56 | $121.80 |
Typical Hold Time | 15 Days | 82 Days |
Enterprise Value | $4.56B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye (MBLY) trades at $7.15, down 4.28% today, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported revenue growth to $1.89B in 2025 but posted a significant net loss of -$392M, with profitability metrics remaining negative. Recent news highlights ADAS business momentum and strategic investments in autonomous mobility, while analyst consensus remains positive with a $10.83 price target.
The stock presents a high-risk opportunity with strong analyst support but persistent profitability challenges. Upside potential exists from autonomous driving adoption and new program ramps, offset by execution risks and negative cash flow projections for 2026. Current valuation below book value offers margin of safety for long-term investors willing to withstand volatility.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
